A competitive intelligence analysis of Apple patent application US20230225659A1 and the strategic role of AirPods Pro 3 in the shift from audio accessories to sensing-driven wearable interfaces.
| Primary patent | US20230225659A1 – Biosignal Sensing Device Using Dynamic Selection of Electrodes |
| Assignee | Apple Inc |
| Product context | AirPods Pro 3 health, fitness, hearing, translation, and AI-linked experiences |
| Analysis type | Single-patent strategic signal analysis, not a full patent landscape |
Apple’s AirPods strategy is no longer just about better sound, stronger noise cancellation, or premium audio positioning. The more interesting signal is that Apple is turning earbuds into a new wearable interface – one that can bring together audio, health sensing, fitness context, hearing support, real-time assistance, and, potentially, deeper biosignal measurement.
That matters because consumer wearables have mostly been led by the wrist. Smartwatches and fitness bands became the default place for heart rate, activity, sleep, recovery, and health notifications. AirPods Pro 3 pushes against that boundary. It does not replace the Apple Watch, but it does show that Apple is willing to move selected health and context-aware features into the ear.
Apple’s patent application US20230225659A1, Biosignal Sensing Device Using Dynamic Selection of Electrodes, adds another layer to this direction. The patent does not show that AirPods Pro 3 uses brain-sensing electrodes today. Public product information does not support that claim. What it does show is that Apple has explored how an ear-worn device could use multiple electrodes and dynamically choose the best subset for biosignal measurement.
The strategic implication is simple: Apple appears to be building options for a future where AirPods are not only an output device, but also a sensing device. For competitive intelligence teams, the more useful question is not whether this exact patent sits inside the current AirPods Pro 3. It is whether Apple is preparing AirPods to compete across a wider wearable stack.
Why This Matters: Earbuds Are Becoming a Different Kind of Wearable
The earbud gives Apple a very different wearable surface from the wrist.
A smartwatch is built for continuity. It has more battery capacity, a larger sensor surface, a display, and a relatively stable position on the wrist. That makes it well suited for all-day health monitoring, workouts, sleep, recovery, notifications, and longer-duration trends.
An earbud is more constrained. It is not usually worn all day, and it has less room for battery, sensors, and thermal management. It also needs to stay comfortable in a much smaller and more variable part of the body. But the earbud sits in a commercially powerful place: in or near the ear, close to the head, and directly connected to audio, voice, calls, translation, hearing support, and AI assistance.
That gives earbuds a different strategic role. They are not smaller smartwatches. They are session-based wearable interfaces. People wear them while exercising, taking calls, commuting, traveling, focusing, gaming, or having conversations. Those are exactly the moments where real-time sensing and real-time feedback can feel valuable.
This is where Apple’s direction starts to make sense. AirPods Pro 3 already brings health and contextual functionality into the ear. The biosignal patent suggests Apple is also studying how the same form factor could support more advanced sensing later. The stronger interpretation is not that earbuds will replace wrist wearables. It is that Apple is distributing wearable intelligence across body locations. The watch can remain the continuous health device. AirPods can become the active-session sensing and assistance device.
How AirPods Pro 3 Works Today: Apple Is Moving Earbuds Into Health and Context
AirPods Pro 3 shows Apple’s near-term commercial direction. The product adds heart-rate sensing during workouts, improved in-ear stability, stronger noise cancellation, better durability for exercise, hearing-related features, and Live Translation through Apple Intelligence.
The heart-rate feature is important because it shows Apple treating the ear as a biometric location. AirPods Pro 3 uses an optical heart-rate sensor that pulses invisible light to measure changes in blood flow. In principle, that is similar to the light-based photoplethysmography approach used by many wearables to estimate heart rate.
Doing this inside an earbud is not a simple copy of a watch sensor. Apple has to manage smaller hardware, tighter battery limits, movement during workouts, variations in ear shape, and a sensor that must work inside a compact audio device.
That makes AirPods Pro 3 commercially significant even before the biosignal patent enters the picture. Apple is showing that premium earbuds can carry health-related features without giving up their core audio role.
For competitors, the benchmark changes. Earbuds can no longer be judged only on ANC, sound quality, call performance, battery life, and fit. Inside Apple’s ecosystem, they are also starting to compete on fitness, health, hearing, translation, and AI-linked assistance.
That is the competitive intelligence signal: Apple is expanding what a premium earbud is expected to do.
What the Patent Adds: Dynamic Electrode Selection for Biosignal Measurement
Apple’s patent application US20230225659A1 goes beyond the optical heart-rate mechanism described for AirPods Pro 3. It describes a wearable electronic device with a housing, an electrode carrier, multiple electrodes positioned across a nonplanar surface, a sensor circuit, and a switching circuit.
The key idea is not simply placing electrodes on an earbud. The key idea is dynamic selection.
The device can include multiple electrodes in different regions. A switching circuit can connect different electrode subsets to the sensor circuit. A processor can test those combinations, evaluate the measurements, identify a suitable subset, and then use that subset to acquire a biosignal.
That matters because biosignal sensing depends heavily on contact quality. Earbuds are not flat medical patches. They sit inside complex ear geometry. Fit changes from person to person. The device can shift during movement. Some electrodes may make strong contact, while others may produce weak or noisy readings.
A fixed electrode pair may work well for one user and poorly for another. Apple’s patent addresses that problem by letting the device choose the electrode pathway that appears most useful under the current conditions.
That is why the patent is strategically interesting. The invention is not just about adding another sensor. It is about solving the reliability problem that could stand between ear-based biosignal sensing and a consumer product.
Why Dynamic Electrode Selection Matters Commercially
The commercial value of biosensing earbuds will not depend only on whether they can detect a signal in ideal conditions. It will depend on whether they can detect that signal reliably across millions of users, ear shapes, workouts, climates, and wear patterns.
That is the product problem Apple’s patent points toward.
- Different users have different ear shapes.
- Earbuds sit differently depending on ear tip size and insertion angle.
- Movement during workouts can change sensor contact.
- Moisture, sweat, skin condition, and pressure can affect readings.
- The device has limited space for electrodes, circuits, battery, antennas, microphones, and audio components.
- Most users will not manually calibrate electrode placement every time they wear earbuds.
Dynamic electrode selection is a way to make the device adapt to the user instead of asking the user to adapt to the device.
That is the real so-what of the patent. If Apple wants ear-based biosignal sensing to be consumer-ready, the device needs a way to determine which contacts are trustworthy. The switching circuit and processor-controlled selection logic are part of that answer.
For R&D teams, the signal is useful. The next stage of competition in smart earbuds may not be about who adds the most sensors. It may be about who can tell which sensor signal is reliable enough to use.
The Difference Between AirPods Pro 3 and the Patent
It is important to keep the product reality separate from the patent signal.
AirPods Pro 3 publicly uses optical heart-rate sensing for workout-related metrics. The patent describes electrode-based biosignal sensing using dynamic electrode subset selection. These are different technical approaches.
AirPods Pro 3 should be treated as evidence of Apple’s commercial movement into health-aware earbuds.
US20230225659A1 should be treated as evidence of Apple’s technical exploration into deeper biosignal sensing through ear-worn devices.
The connection between the two is strategic, not necessarily implementation-based. Both point toward the same broader direction: Apple is making the ear a more important interface for sensing, assistance, and health-related experiences.
This distinction makes the analysis stronger. The article does not need to claim that AirPods Pro 3 already has brain-sensing electrodes. The safer and more valuable claim is that Apple’s current product direction and patent activity are converging around the same long-term theme: earbuds as intelligent wearable interfaces.
Why Earbuds Can Create an Edge That Watches Cannot Fully Replicate
The wrist is a strong wearable location, but it does not own every use case. Earbuds have advantages that wrist devices cannot fully replicate.
- Audio feedback is built in. A watch can display information or vibrate. Earbuds can deliver real-time coaching, translated speech, hearing enhancement, noise control, and contextual prompts without asking the user to look at a screen.
- Earbuds are used during high-intent sessions. People wear them while exercising, commuting, working, calling, gaming, or traveling. These are commercially valuable moments because users may be open to assistance, monitoring, or feedback.
- They sit close to the head. That makes them relevant for hearing, voice, conversation, spatial audio, head movement, and potentially certain biosignal measurements.
- They can operate as a paired architecture. A left and right earbud can create a two-point system. Apple’s patent describes configurations where components may be worn on or in both ears, with active and reference electrodes distributed across them.
- They are already tied into Apple’s ecosystem. A health or AI feature in AirPods can connect to iPhone, Apple Watch, Fitness, Health, Siri, Apple Intelligence, and hearing-related experiences. That is difficult for standalone device makers to match.
This is where Apple’s competitive edge could emerge. The advantage is not simply that Apple can put sensors into earbuds. The advantage is that Apple can connect earbud sensing to a broader software, health, and device ecosystem.
Competitive Intelligence View: Who Should Pay Attention?
The obvious competitors are premium earbud companies: Samsung, Sony, Bose, Huawei, Xiaomi, Nothing, and other TWS brands. But the competitive impact could reach well beyond earbuds.
Premium Earbud Companies
Premium earbud makers have traditionally competed on sound quality, ANC, comfort, call quality, battery life, and device ecosystem. AirPods Pro 3 raises the bar by adding health and contextual features into the same product category.
If Apple continues in this direction, competitors will have to decide whether they remain audio-first or become sensing-and-assistance devices.
The risk is that premium may no longer mean better audio alone. It may mean better integration of audio, health, translation, hearing, fitness, and AI assistance.
Smartwatch and Fitness Band Companies
AirPods are unlikely to replace smartwatches for continuous monitoring. Watches and fitness bands remain better suited for all-day tracking, sleep, recovery, and longer-duration health metrics.
But AirPods can take over selected session-based use cases. Workout heart-rate tracking is one example. Real-time coaching could be another. Focus, fatigue, communication, hearing support, and translation could also become earbud-led experiences.
The threat is not full replacement. The threat is use-case erosion. If AirPods become good enough for certain active health and assistance moments, some users may see less need for a separate low-end fitness wearable.
Hearing-Assist and Translation Device Makers
Apple’s hearing-related features and Live Translation create pressure on specialized assistive audio and translation devices.
Specialized products may still win in regulated, clinical, professional, or high-accuracy scenarios. But Apple can absorb many mainstream use cases by bundling them into a product users already own.
That is a classic platform advantage. Apple does not need AirPods to be the best dedicated translation device or the best hearing-assist device for every user. It only needs them to be good enough for a large share of everyday situations.
Biosignal and Neurotechnology Startups
The patent should also be monitored by companies working on ear-based EEG, neural interfaces, cognitive-state detection, stress tracking, fatigue monitoring, or electrophysiological wearables.
Apple’s patent claims include biosignal measurement and brain electrical activity. That does not mean Apple is entering neurotechnology commercially tomorrow. It does mean Apple is building IP optionality around ear-worn biosignal architectures.
For startups, the freedom-to-operate question matters. If Apple keeps filing in this area, the patent landscape around adaptive electrodes, earbud-based biosensing, and signal selection could become more crowded.
To assess whether Apple is building a defensible patent position around biosensing earbuds, the next step is to map related filings, continuations, international family members, claim overlap, and competitor filings around adaptive electrodes, ear-based EEG, contact impedance, and biosignal validation.
How Apple Could Build a Competitive Edge
- Hardware miniaturization. AirPods Pro 3 already shows Apple integrating additional sensing into a compact earbud form factor. That is hard because every component competes with audio drivers, microphones, chips, battery, antennas, and fit structures. If Apple can keep adding sensing hardware without hurting comfort or audio performance, it gains a meaningful design advantage.
- Adaptive sensing architecture. The patent’s dynamic electrode selection mechanism points to a deeper advantage. Future biosensing earbuds will need to manage inconsistent contact and noisy signals. A system that can test electrode combinations, select useful contacts, and reject poor signal paths may produce more reliable data.
- Ecosystem-level data fusion. Apple does not need AirPods to operate alone. AirPods can work with iPhone, Apple Watch, Fitness, Health, and Apple Intelligence. The watch may remain better for continuous monitoring, while AirPods may be stronger during workouts, calls, translation, and hearing-related moments. The ecosystem can decide which device provides the most useful signal in context.
- User trust and privacy positioning. Health and biosignal data require trust. Apple has spent years positioning itself around privacy and integrated health experiences. If AirPods eventually collect more sensitive biosignals, user trust will become central to adoption. Competitors may copy hardware features faster than they can copy ecosystem trust and health-data handling.
Why This Patent Is Strategically Strong Despite Being a Single-Patent Signal
A single patent should not be treated as a full portfolio trend. Still, this patent is meaningful because it sits at the intersection of several important technology directions:
- ear-based sensing,
- adaptive electrodes,
- biosignal measurement,
- brain electrical activity,
- wireless earbuds or headphones,
- active and reference electrode selection, and
- system-level signal optimization.
The patent is not narrow in the way a simple component patent might be. It describes a sensing architecture: electrode placement, switching, processor control, signal testing, subset selection, and biosignal acquisition.
That system-level nature makes it more strategically relevant. Competitors can often design around individual sensor placements. It may be harder to design around the broader idea of adaptive electrode selection if that approach becomes central to earbud biosensing.
For IP teams, the next step is to monitor whether Apple expands this into a broader family. Continuations, international filings, related applications, or future claims around EEG, EMG, EOG, fit detection, contact impedance, and signal validation would strengthen the view that Apple is building a patent fence around biosensing earbuds.
Strategic Implications for IP, R&D, and Business Teams
- For IP teams, the key task is to monitor whether this patent becomes part of a larger ear-based biosensing portfolio. One patent is a signal. A cluster of continuations and related filings would look more like a strategy.
- For R&D teams, the patent highlights the real technical battleground: signal reliability. Adding electrodes is not enough. The device must know which electrodes are making useful contact and which signals are trustworthy.
- For product teams, the opportunity is not to copy smartwatch features into earbuds. Earbuds should be designed around use cases where they are naturally stronger: real-time coaching, translation, hearing assistance, calls, active workouts, and contextual audio feedback.
- For business teams, the risk is category convergence. AirPods can pull value from multiple adjacent markets, including premium audio, fitness tracking, hearing assistance, translation devices, and potentially biosignal wearables.
- For competitive intelligence teams, the patent should be tracked alongside product launches, teardown findings, health-feature updates, regulatory signals, and competitor filings. The strongest signal will come when patent activity and product behavior begin to align more directly.
The Real Signal Is Not Brain-Sensing AirPods – It Is Apple’s Shift Toward Ear-Based Wearable Intelligence
The most useful takeaway is not that AirPods Pro 3 is a brain-sensing device. That would overstate what is publicly known.
The more important takeaway is that Apple is expanding the role of AirPods in the wearable stack. AirPods Pro 3 shows the commercial direction through health sensing, workout use, hearing features, translation, and AI-linked experiences. US20230225659A1 shows the technical direction through adaptive electrode-based biosignal sensing.
Together, they suggest that Apple sees the ear as more than an audio endpoint. It can become a sensing location, an assistance layer, and a real-time interface.
For competitors, the threat is not immediate replacement of smartwatches or specialized devices. The threat is gradual use-case absorption. If AirPods can handle more health, communication, translation, hearing, and eventually biosignal functions, Apple can expand the value of earbuds without asking users to adopt a new device category.
That is the competitive intelligence signal: the wearable market is moving beyond the wrist, and Apple is positioning AirPods as one of the devices that could define that shift.
Where This Analysis Should Go Next
This analysis is based on one Apple patent application and public AirPods Pro 3 product signals. It should be treated as a directional intelligence brief, not a complete landscape.
A deeper analysis would require:
- mapping Apple’s related biosensing and earbud patent families,
- checking continuation and family expansion activity,
- analyzing forward citations and citing assignees,
- comparing Apple’s filings against Samsung, Sony, Bose, Huawei, Xiaomi, Garmin, Oura, Whoop, Fitbit, Sonova, GN, and other hearing or biosignal players, and
- identifying claim overlap around ear-based electrodes, EEG, contact impedance, sensor selection, and wearable health data processing.
For updated patent activity, competitor movement, claim mapping, and recent innovation signals in biosensing earbuds and next-generation wearables, request the updated landscape analysis.
